At the NIH Regional Seminar this past May, I had the pleasure of giving the keynote talk and presenting different perspectives on how NIH can further the impact of our research funding. …. My staff recorded this talk and has made it available to you on the NIH Grants YouTube channel. If you’re interested in the topics covered here on the blog …. Continue reading
At the Advisory Committee to the Director meeting last week, NIH Principal Deputy Director Dr. Larry Tabak presented a new NIH initiative to strengthen the biomedical workforce. This presentation followed extensive discussions with stakeholders both here through this blog, at stakeholder meetings, and at NIH advisory council meetings over the last month. We heard unequivocal endorsements for supporting early-career and mid-career researchers given the hypercompetitive funding environment —a challenge we have addressed many times in my blog posts. However, many voiced concerns about our taking a formulaic approach to capping grant funding and called on us to be more direct in enabling greater support for the next generation of biomedical researchers. For this reason, we have shifted our approach to a focused initiative to support early- and mid-career investigators. …. Continue reading
Working with NIH applicants and awardees as an extramural program division director, I often shared the NIH RePORTER resource as a tool for exploring the research topics NIH supports. Learning what projects we support, using a robust database of historical and newly-funded projects (updated weekly), provides researchers valuable insight as they consider developing their own research programs and applications for funding.
Another valuable tool which you might be familiar with is Federal RePORTER, which expands the RePORTER concept to support searching over 800,000 projects across 17 Federal research agencies, with trans-agency data updated annually. As Federal RePORTER recently received an update to introduce some new functions and additional agency data we’d like to highlight some of the ways it helps both the public and scientific researchers alike …. Continue reading
We appreciate the many thoughtful comments posted to the blog about working together to improve NIH funding support for early- and mid-career investigators to stabilize the biomedical workforce and research enterprise using a measure called the Grant Support Index (GSI). Some clear themes have emerged, including: …. Continue reading
NIH realizes that, as stewards of the American investment in biomedical sciences, we must do all we can to protect the future of the biomedical research enterprise, taking additional measures regardless of our budget situation. In the opening pages of this blog, we noted that our increasingly hypercompetitive system is threatening the future of biomedical research and of the hundreds of thousands of scientists who we look to for discovering tomorrow’s cures. This is a strange irony, given that the last 25-50 years have been times of extraordinary discovery and progress in basic, translational, and applied science. Death rates from cardiovascular disease have plummeted, and death rates from cancer are falling steadily. Scientists have a much deeper understanding of human biology to the point where this knowledge can drive the design of drugs and biologics. Big data and high-throughput technologies now enable rapid development and testing of hypotheses that previously would have taken years. The successes are myriad. But so are the problems, problems so real that some have gone so far as to write, “It is time to confront the dangers at hand and rethink some fundamental features of the US biomedical research system.” …. Continue reading
Earlier this year I wrote a post about the 21st Century Cures Act and its changes that directly affect the NIH. One part of this new legislation contains provisions to improve clinical research and privacy through certificates of confidentiality.
Currently, certificates of confidentiality (or “CoCs”) are provided upon request to researchers collecting sensitive information about research participants. Soon, CoCs will be automatically provided for NIH-supported research, as set forth in the 21st Century Cures Act. …. Continue reading
Measuring the impact of NIH grants is an important input in our stewardship of research funding. One metric we can use to look at impact, discussed previously on this blog, is the relative citation ratio (or RCR). This measure – which NIH has made freely available through the iCite tool – aims to go further than just raw numbers of published research findings or citations, by quantifying the impact and influence of a research article both within the context of its research field and benchmarked against publications resulting from NIH R01 awards.
In light of our more recent posts on applications and resubmissions, we’d like to go a step further by looking at long-term bibliometric outcomes as a function of submission number. In other words, are there any observable trends in the impact of publications resulting from an NIH grant funded as an A0, versus those funded as an A1 or A2? And does that answer change when we take into account how much funding each grant received? …. Continue reading
Imagine this: you’re a reviewer on an NIH study section, and receive a greeting card from the Principal Investigator (PI) on an application you are reviewing. A note written inside the card asks that your look favorably upon the application, and in return, the PI would put in a good word with his friend serving on your promotion committee. Do you accept the offer, or just ignore it? Or, do you report it? …. Or maybe several days after the initial peer review of your application, you receive a phone call from a colleague you haven’t spoken to in quite a while. The colleague is excited about a new technique you developed and wishes to collaborate. You realize the only place you’ve disclosed this new technique is in your recently reviewed NIH grant application. What do you do? …. Continue reading
The role of preprints — complete and public draft manuscripts which have not gone through the formal peer review, editing, or journal publishing process – continues to be a hot topic in the biological and medical sciences. In January, three major biomedical research funders – HHMI, the MRC, and the Wellcome Trust, changed their policies to allow preprints to be cited in their progress reports and applications.
Thinking about preprints also raises questions about the broader class of interim research products, and the role they should play in NIH processes. Other interim products include products like preregistration of protocols or research methods, to publicly declare key elements of a research project in advance. While, under current policy, NIH does not restrict items cited in the research plan of an application, applicants cannot claim preprints in biosketches or progress reports.
So, in October, we issued a call for comments to get a fuller understanding of how the NIH-supported research community uses and thinks about interim research products. Today I’d like to follow up with what we’ve learned from your input, and the policy changes this feedback suggests. …. Continue reading
In a previous blog, we described the outcomes of grant applications according to the initial peer review score. Some of you have wondered about the peer review scores of amended (“A1”) applications. More specifically, some of you have asked about … Continue reading